GH Guardant Health Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GH

Price (delayed)

$133.19

Market cap

$17.66B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.39

Enterprise value

$18.24B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 23

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health ...

Highlights
The gross profit has grown by 48% YoY and by 11% from the previous quarter
Guardant Health's revenue has increased by 40% YoY and by 10% from the previous quarter
GH's equity has shrunk by 82% QoQ but it is up by 28% YoY
Guardant Health's quick ratio has increased by 14% YoY but it has decreased by 3.3% from the previous quarter
The debt is up by 31% year-on-year
Guardant Health's net income has decreased by 4.1% QoQ and by 4% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.guardanthealth.com
Peers: NEOG NTRA MYGN

Key stats

What are the main financial stats of GH

GH stock price

How has the Guardant Health stock price performed over time
Intraday
4.85%
1 week
-0.02%
1 month
46.09%
1 year
178.87%
YTD
30.4%
QTD
44.19%

Financial performance

How have Guardant Health's revenue and profit performed over time
Revenue
$1.08B
Gross profit
$701.01M
Operating income
-$447.56M
Net income
-$433.19M
Gross margin
64.9%
Net margin
-40.1%
The gross profit has grown by 48% YoY and by 11% from the previous quarter
Guardant Health's revenue has increased by 40% YoY and by 10% from the previous quarter
The company's operating margin rose by 30% YoY and by 7% QoQ
The net margin is up by 25% year-on-year and by 5% since the previous quarter

Price vs fundamentals

How does GH's price correlate with its fundamentals

Growth

What is Guardant Health's growth rate over time

Valuation

What is Guardant Health stock price valuation
P/E
N/A
P/B
N/A
P/S
16.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.88
The EPS has declined by 2.1% since the previous quarter
GH's equity has shrunk by 82% QoQ but it is up by 28% YoY
The P/S is 51% above the last 4 quarters average of 10.2 and 29% above the 5-year quarterly average of 12.0
Guardant Health's revenue has increased by 40% YoY and by 10% from the previous quarter

Efficiency

How efficient is Guardant Health business performance
The return on sales is up by 25% year-on-year and by 5% since the previous quarter
Guardant Health's ROIC has increased by 9% YoY and by 2.3% from the previous quarter
GH's ROA is up by 5% since the previous quarter and by 5% year-on-year

Dividends

What is GH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GH.

Financial health

How did Guardant Health financials performed over time
Guardant Health's total assets is 9% less than its total liabilities
Guardant Health's total assets has increased by 42% YoY but it has decreased by 4.9% from the previous quarter
The company's total liabilities rose by 31% YoY
GH's debt to equity has dropped by 82% year-on-year but it is up by 45% since the previous quarter
GH's equity has shrunk by 82% QoQ but it is up by 28% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.